A randomized, placebo-controlled, phase II, presurgical biomarker trial of Celecoxib versus exemestane in postmenopausal breast cancer patients

Research output: Contribution to journalArticlepeer-review

Abstract

In breast cancer presurgical trials, the Ki-67 labeling index predicts disease outcome and offers clues to the preventive potential of drugs. We conducted a placebo-controlled trial to evaluate the activity of exemestane and celecoxib before surgery. The main endpoint was the change in Ki-67. Secondary endpoints were the modulation of circulating biomarkers. Postmenopausal women with histologically confirmed estrogen receptor-positive breast cancer were randomly assigned to exemestane 25 mg/day (n = 50), or celecoxib 800 mg/day (n = 50), or placebo (n = 25) for 6 weeks before surgery. Changes in biomarkers were analyzed through an ANCOVA model adjusting for baseline values. Exemestane showed a median absolute 10% reduction in Ki-67 [from22 (interquartile range, IQR, 16-27), to 8 (IQR 5-18)], and a 15% absolute reduction in PgR expression [from 50 (IQR 3-90) to 15 (IQR-0-30)] after 6 weeks of treatment. Exemestane significantly increased testosterone [median change 0.21 ng/mL, (IQR 0.12-0.35)], decreased SHBG [median change-14.6 nmol/L, (IQR-23.1 to-8.6)], decreased total and HDL cholesterol by-10 mg/dL (IQR-21-2) and-7 mg/dL, (IQR-14 to-2), respectively. Triglycerides were reduced by both agents [median change-0.5 mg/dL (IQR-17.5-13.5) and-8 mg/dL (IQR-28-9) for celecoxib and exemestane, respectively]. Exemestane showed a remarkable antiproliferative effect on breast cancer, whereas celecoxib did not affect breast cancer proliferation. Given the proven preventive efficacy of exemestane, these findings support the use of Ki-67 to explore the optimal exemestane dose and schedule in the prevention setting. Cancer Prev Res; 9(5); 349-56.

Original languageEnglish
Pages (from-to)349-356
Number of pages8
JournalCancer Prevention Research
Volume9
Issue number5
DOIs
Publication statusPublished - May 1 2016

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'A randomized, placebo-controlled, phase II, presurgical biomarker trial of Celecoxib versus exemestane in postmenopausal breast cancer patients'. Together they form a unique fingerprint.

Cite this